Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
MEN-2312 by Stemline Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
MEN-2312 is under clinical development by Stemline Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
Data Insights
MEN-2312 by Stemline Therapeutics for Solid Tumor: Likelihood of Approval
MEN-2312 is under clinical development by Stemline Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...